60 Degrees Pharmaceuticals, Inc.

NasdaqCM:SXTP Stock Report

Market Cap: US$5.1m

60 Degrees Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:SXTP Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Dec 25BuyUS$7,759Geoffrey DowIndividual2,417.5US$3.21
11 Dec 25BuyUS$12,204Geoffrey DowIndividual3,240.75US$3.80
03 Jun 25BuyUS$14,410Cheryl XuIndividual1,250US$11.60

Insider Trading Volume

Insider Buying: SXTP insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SXTP?
Owner TypeNumber of SharesOwnership Percentage
Public Companies8,4750.658%
Individual Insiders24,2691.89%
Institutions65,2615.07%
VC/PE Firms113,8868.85%
General Public1,075,30083.5%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 249.6%.

Top Shareholders

Top 18 shareholders own 16.46% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.85%
Heights Capital Management, Inc.
113,886US$449.8k0%0.16%
3.23%
Orca Capital GmbH
41,557US$164.2k0%2.58%
1.5%
Armistice Capital LLC
19,339US$76.4k0%no data
1.37%
Geoffrey Dow
17,684US$69.9k59%no data
0.66%
Knight Therapeutics Inc.
8,475US$33.5k0%no data
0.31%
Cheryl Xu
3,954US$15.6k0%no data
0.24%
Geode Capital Management, LLC
3,112US$12.3k0%no data
0.1%
Tyrone Miller
1,319US$5.2k0%no data
0.088%
Kristen Landon
1,135US$4.5k0%no data
0.061%
Tower Research Capital Europe Limited
785US$3.1k21%no data
0.029%
UBS Asset Management AG
369US$1.5k0%no data
0.0046%
Charles Allen
59US$232.90%no data
0.0046%
Stephen Toovey
59US$232.90%no data
0.0046%
Paul Field
59US$232.90%no data
0.0037%
Citigroup Inc.
47US$185.60%no data
0.0019%
Osaic Wealth, Inc.
25US$98.60%no data
0.0015%
The Vanguard Group, Inc.
20US$78.8-31%no data
0.00054%
Bank of America Corporation
7US$27.5133%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/13 05:41
End of Day Share Price 2026/02/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

60 Degrees Pharmaceuticals, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lucas WardAscendiant Capital Markets LLC
Matthew KellerH.C. Wainwright & Co.